What Macrogenics Inc does.

Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. “MacroGenics ® , the MacroGenics logo, DART ® , TRIDENT ® and the phrases Breakthrough Biologics, Life-Changing Medicines ® and Developing Breakthrough Biologics, Life-Changing Medicines ® are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.

We are a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms. We are currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which we refer to as DART and TRIDENT molecules). The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates – three of which have received marketing approval by the U.S. Food and Drug Administration (FDA) – and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided us with over $1.6 billion of non-dilutive funding since our inception in 2000, and have enabled us to leverage the additional expertise of our collaborators to advance the development of multiple partnered product candidates. In addition, we operate a commercial-scale cGMP antibody manufacturing facility in our Maryland headquarters. We have utilized the facility to support our clinical programs and we also provide outsourced contract development and manufacturing services to our collaborators and other third parties for commercial and clinical products to offset a significant portion of the operating costs of this facility.

Revenue and profit, by fiscal year.

More on MGNX.

• Macrogenics Inc summary
• Macrogenics Inc financial statements
• Macrogenics Inc key metrics
• Macrogenics Inc health scores and style box
• Macrogenics Inc earnings
• Macrogenics Inc dividends
• Macrogenics Inc valuation
• Macrogenics Inc ownership and insiders
• Macrogenics Inc peers

Figures from Macrogenics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.